January 02, 2026 05:25 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Epicentre of misgovernance’: Rahul Gandhi blasts Madhya Pradesh govt over deadly water contamination | After Mamdani's letter, 8 US lawmakers push 'fair trial' for Umar Khalid amid UAPA case | ‘Bad neighbours’: Jaishankar shreds Pakistan, defends India’s right to act against cross-border terror | New Year gift for rail passengers! PM Modi to flag off first Vande Bharat sleeper in January | ‘Rs 1 lakh for his tongue’: Shah Rukh Khan faces threats after KKR signs Mushtafizur Rahman amid violence against Hindus in Bangladesh | New Year horror in Switzerland: Dozens feared dead in Crans-Montana bar explosion | Tobacco stocks crushed as govt slaps fresh excise duty from Feb 1 | Vodafone Idea shares explode 10% after surprise settlement and govt relief boost | No third party involved: India govt sources refute China’s Operation Sindoor ceasefire claim | Amit Shah blasts TMC over border fencing; Mamata fires back on Pahalgam and Delhi blast

Human antibody discovery could save lives from fungal killer: Study

| @indiablooms | Dec 12, 2018, at 04:01 pm

London, Dec 12 (IBNS): A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Despite public health efforts, many people who get fungal infections in their blood streams die, even if they can be identified and treated with antifungal drugs. These therapies are often ineffective on their own and increasingly the infections are becoming resistant to treatment with some of the front line antifungal drugs.

The new technique, within the Medical Research Council Centre for Medical Mycology at the University of Aberdeen and funded by the Wellcome Trust and Medical Research Council, is the first to successfully use antibodies that are cloned from patients who have recovered from an infection caused by the fungus Candida.  In addition to causing thrush in more than one hundred million every year, this fungus is also the fourth leading cause of serious life-threatening bloodstream infections in developed countries. In laboratory experiments, the research team used these cloned antibodies to successfully protect animals from Candida bloodstream infections and demonstrate their potential in both treating and diagnosing Candida infections.

Dr Fiona Rudkin, who led the research and is currently heading up the creation of an Aberdeen-based spinout company to conduct the next phase of therapeutic development, said: “There is an urgent need to develop better ways for diagnosing and treating life-threatening fungal infections.  Human antibodies have revolutionised the way many cancers are treated and diagnosed.  This research marks a huge step towards using similar antibody-based approaches to tackle fungal infections.  These antibodies will now be developed as novel antifungal drugs through the creation of mycoBiologics – a new spin out company based in Aberdeen focused on improving the outcome of patients suffering from life-threatening fungal infections.”

Professor Neil Gow of the University of Exeter, who supervised the research while at Aberdeen, said: “Globally, fungal infections are under-recognised as a major killer. They’re hard to detect and for every day we fail to diagnose a serious fungal infection, the chances of survival diminishes. This research brings us a step closer to a day when we can use the antibodies that are generated by the human body to diagnose and treat fungal infections.”

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.